Edition:
India

People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

4.44USD
24 Feb 2020
Change (% chg)

-- (--)
Prev Close
$4.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
449,869
52-wk High
$14.77
52-wk Low
$2.27

Pandita, Kanwal 

Dr. Kanwal Pandita is Managing Partner - RAKS of the Company. Dr. Kanwal Pandita has served with Amneal Pharmaceuticals LLC, USA, since 2008. He founded and established Raks Pharma Pvt Ltd, (an API Division of Amneal LLC, USA) and in 2011 joined as Managing Director. He is an accomplished pharmaceutical executive with extensive experience managing the API function and audits originating from the USFDA, EDQM, WHO, Korean FDA etc. Prior to joining Amneal, Dr. Pandita held senior positions in consultancy, operations, and business development at OSB Pharmaceuticals LLC USA, Morepen Inc. USA, Zydus Pharmaceuticals Inc. (USA), Cadila Healthcare Ltd. India and Ranbaxy Laboratories Ltd. India. Dr. Pandita has more than 33 years of experience in the global pharmaceutical industry, has travelled extensively, and has many patents and publications to his credit. He holds a Master’s degree in Organic Chemistry, M.Phil. and Ph.D. in Medicinal/Synthetic Organic Chemistry from RRL, Jammu (a Division of Council of Scientific and Industrial Research, India).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --